Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells

Alexey A. Leontovich, Jeffrey L Salisbury, Massimiliano Veroux, Tiziano Tallarita, Daniel D Billadeau, James McCubrey, James Ingle, Evanthia Galanis, Antonio D'Assoro

Research output: Contribution to journalArticle

13 Citations (Scopus)

Abstract

Centrosome amplification plays a key role in the origin of chromosomal instability (CIN) during cancer development and progression. In this study, MCF-7 breast cancer cell lines harboring abrogated p53 function (vMCF-7 DNp53) were employed to investigate the relationship between induction of genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A oncogenic signalings and development of centrosome amplification. Introduction of genotoxic stress in the vMCF-7DNp53 cell line by treatment with hydroxyurea (HU) induced centrosome amplification that was mechanistically linked to Aurora-A kinase activity. In cells carrying defective p53, the develop ment of centrosome amplification also occurred following treatment with another DNA damaging agent, methotrexate. Importantly, we demonstrated that Aurora-A kinase-induced centrosome amplification was mediated by Cdk2 kinase since molecular inhibition of Cdk2 activity by SU9516 suppressed Aurora-A centrosomal localization and consequent centro some amplification. In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression. Taken together, these findings demonstrate a novel positive feed-back loop between cyclin-A/Cdk2 and Aurora-A pathways in the development of centrosome amplification in breast cancer cells. They also provide the translational rationale for targeting 'druggable cell cycle regulators' as an innovative therapeutic strategy to inhibit centrosome amplification and CIN in breast tumors resistant to conventional chemotherapeutic drugs.

Original languageEnglish (US)
Pages (from-to)1785-1788
Number of pages4
JournalOncology Reports
Volume29
Issue number5
DOIs
StatePublished - May 2013

Fingerprint

Aurora Kinase A
Centrosome
Cyclin A
Breast Neoplasms
Chromosomal Instability
DNA Damage
Cell Line
Hydroxyurea
Methotrexate
Cell Cycle
Phosphotransferases
DNA

Keywords

  • Aurora-A
  • Breast cancer
  • Cdk2
  • Centrosome amplification
  • Genotoxic stress

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells. / Leontovich, Alexey A.; Salisbury, Jeffrey L; Veroux, Massimiliano; Tallarita, Tiziano; Billadeau, Daniel D; McCubrey, James; Ingle, James; Galanis, Evanthia; D'Assoro, Antonio.

In: Oncology Reports, Vol. 29, No. 5, 05.2013, p. 1785-1788.

Research output: Contribution to journalArticle

@article{283eb5c5003d47dc839675311a424def,
title = "Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells",
abstract = "Centrosome amplification plays a key role in the origin of chromosomal instability (CIN) during cancer development and progression. In this study, MCF-7 breast cancer cell lines harboring abrogated p53 function (vMCF-7 DNp53) were employed to investigate the relationship between induction of genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A oncogenic signalings and development of centrosome amplification. Introduction of genotoxic stress in the vMCF-7DNp53 cell line by treatment with hydroxyurea (HU) induced centrosome amplification that was mechanistically linked to Aurora-A kinase activity. In cells carrying defective p53, the develop ment of centrosome amplification also occurred following treatment with another DNA damaging agent, methotrexate. Importantly, we demonstrated that Aurora-A kinase-induced centrosome amplification was mediated by Cdk2 kinase since molecular inhibition of Cdk2 activity by SU9516 suppressed Aurora-A centrosomal localization and consequent centro some amplification. In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression. Taken together, these findings demonstrate a novel positive feed-back loop between cyclin-A/Cdk2 and Aurora-A pathways in the development of centrosome amplification in breast cancer cells. They also provide the translational rationale for targeting 'druggable cell cycle regulators' as an innovative therapeutic strategy to inhibit centrosome amplification and CIN in breast tumors resistant to conventional chemotherapeutic drugs.",
keywords = "Aurora-A, Breast cancer, Cdk2, Centrosome amplification, Genotoxic stress",
author = "Leontovich, {Alexey A.} and Salisbury, {Jeffrey L} and Massimiliano Veroux and Tiziano Tallarita and Billadeau, {Daniel D} and James McCubrey and James Ingle and Evanthia Galanis and Antonio D'Assoro",
year = "2013",
month = "5",
doi = "10.3892/or.2013.2313",
language = "English (US)",
volume = "29",
pages = "1785--1788",
journal = "Oncology Reports",
issn = "1021-335X",
publisher = "Spandidos Publications",
number = "5",

}

TY - JOUR

T1 - Inhibition of Cdk2 activity decreases Aurora-A kinase centrosomal localization and prevents centrosome amplification in breast cancer cells

AU - Leontovich, Alexey A.

AU - Salisbury, Jeffrey L

AU - Veroux, Massimiliano

AU - Tallarita, Tiziano

AU - Billadeau, Daniel D

AU - McCubrey, James

AU - Ingle, James

AU - Galanis, Evanthia

AU - D'Assoro, Antonio

PY - 2013/5

Y1 - 2013/5

N2 - Centrosome amplification plays a key role in the origin of chromosomal instability (CIN) during cancer development and progression. In this study, MCF-7 breast cancer cell lines harboring abrogated p53 function (vMCF-7 DNp53) were employed to investigate the relationship between induction of genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A oncogenic signalings and development of centrosome amplification. Introduction of genotoxic stress in the vMCF-7DNp53 cell line by treatment with hydroxyurea (HU) induced centrosome amplification that was mechanistically linked to Aurora-A kinase activity. In cells carrying defective p53, the develop ment of centrosome amplification also occurred following treatment with another DNA damaging agent, methotrexate. Importantly, we demonstrated that Aurora-A kinase-induced centrosome amplification was mediated by Cdk2 kinase since molecular inhibition of Cdk2 activity by SU9516 suppressed Aurora-A centrosomal localization and consequent centro some amplification. In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression. Taken together, these findings demonstrate a novel positive feed-back loop between cyclin-A/Cdk2 and Aurora-A pathways in the development of centrosome amplification in breast cancer cells. They also provide the translational rationale for targeting 'druggable cell cycle regulators' as an innovative therapeutic strategy to inhibit centrosome amplification and CIN in breast tumors resistant to conventional chemotherapeutic drugs.

AB - Centrosome amplification plays a key role in the origin of chromosomal instability (CIN) during cancer development and progression. In this study, MCF-7 breast cancer cell lines harboring abrogated p53 function (vMCF-7 DNp53) were employed to investigate the relationship between induction of genotoxic stress, activation of cyclin-A/Cdk2 and Aurora-A oncogenic signalings and development of centrosome amplification. Introduction of genotoxic stress in the vMCF-7DNp53 cell line by treatment with hydroxyurea (HU) induced centrosome amplification that was mechanistically linked to Aurora-A kinase activity. In cells carrying defective p53, the develop ment of centrosome amplification also occurred following treatment with another DNA damaging agent, methotrexate. Importantly, we demonstrated that Aurora-A kinase-induced centrosome amplification was mediated by Cdk2 kinase since molecular inhibition of Cdk2 activity by SU9516 suppressed Aurora-A centrosomal localization and consequent centro some amplification. In addition, we employed vMCF-7DRaf-1 cells that display high levels of endogenous cyclin-A and demonstrated that molecular targeting of Aurora-A by Alisertib reduces cyclin-A expression. Taken together, these findings demonstrate a novel positive feed-back loop between cyclin-A/Cdk2 and Aurora-A pathways in the development of centrosome amplification in breast cancer cells. They also provide the translational rationale for targeting 'druggable cell cycle regulators' as an innovative therapeutic strategy to inhibit centrosome amplification and CIN in breast tumors resistant to conventional chemotherapeutic drugs.

KW - Aurora-A

KW - Breast cancer

KW - Cdk2

KW - Centrosome amplification

KW - Genotoxic stress

UR - http://www.scopus.com/inward/record.url?scp=84876247134&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84876247134&partnerID=8YFLogxK

U2 - 10.3892/or.2013.2313

DO - 10.3892/or.2013.2313

M3 - Article

C2 - 23446853

AN - SCOPUS:84876247134

VL - 29

SP - 1785

EP - 1788

JO - Oncology Reports

JF - Oncology Reports

SN - 1021-335X

IS - 5

ER -